Acrotech Brings Difamilast 1% Ointment for Atopic Dermatitis to US
Key Takeaways
- Acrotech Biopharma has launched ADQUEY (difamilast 1%) ointment in the United States for mild-to-moderate atopic dermatitis in adults and children aged 2 years and older.
- The nonsteroidal topical therapy was originally discovered by Otsuka Pharmaceutical and licensed to Acrotech for US commercialization.
- The launch marks Acrotech’s entry into US dermatology and is being supported by a newly established dermatology business unit.
Acrotech Biopharma Inc. announced the United States launch of ADQUEY (difamilast 1%) ointment, a nonsteroidal topical treatment for mild-to-moderate atopic dermatitis (AD) in adults and pediatric patients aged 2 years and older.
Difamilast was originally developed by Otsuka Pharmaceutical and licensed to Acrotech for commercialization in the US. The launch also marks Acrotech’s entry into the US dermatology market and the establishment of a dedicated dermatology business unit.
ADQUEY Launch Expands Acrotech Into Atopic Dermatitis
According to the company, the new dermatology unit will provide specialized commercial capabilities spanning marketing, sales, and field-based engagement. Acrotech said the organization will initially focus on building awareness of ADQUEY, engaging dermatology health care professionals, and supporting patients while establishing infrastructure for potential expansion within specialty dermatology.
Acrotech cited IQVIA MAT data estimating the relevant market at approximately $1.3 billion for the 12 months ending July 2026. Additional context regarding the methodology and product categories included in that estimate was not provided in the announcement.
“The launch of ADQUEY is an important milestone for Acrotech and marks our entry into the US dermatology market with a differentiated treatment option for patients living with atopic dermatitis,” Ashish Anvekar, president of Acrotech Biopharma, said in the announcement.
Anvekar added that the company is establishing a dermatology platform intended to support ADQUEY while creating capabilities to pursue additional opportunities in dermatologic care.